Fredag 2 Oktober | 00:55:25 Europe / Stockholm
Est. tid*
2027-02-26 08:30 Bokslutskommuniké 2026
2026-11-20 08:00 Kvartalsrapport 2026-Q3
2026-08-24 - Kvartalsrapport 2026-Q2
2026-05-25 - Årsstämma
2026-05-25 - Kvartalsrapport 2026-Q1
2026-04-13 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2026-04-13 - Extra Bolagsstämma 2026
2026-02-06 - Bokslutskommuniké 2025
2025-10-24 - Kvartalsrapport 2025-Q3
2025-08-04 - Extra Bolagsstämma 2025
2025-07-11 - Kvartalsrapport 2025-Q2
2025-04-10 - Årsstämma
2025-04-10 - Kvartalsrapport 2025-Q1
2025-04-04 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2025-02-05 - Bokslutskommuniké 2024
2024-10-25 - Kvartalsrapport 2024-Q3
2024-07-12 - Kvartalsrapport 2024-Q2
2024-05-22 - Extra Bolagsstämma 2024
2024-04-24 - Kvartalsrapport 2024-Q1
2024-04-10 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2024-04-09 - Årsstämma
2024-02-09 - Bokslutskommuniké 2023
2023-10-27 - Kvartalsrapport 2023-Q3
2023-07-14 - Kvartalsrapport 2023-Q2
2023-05-03 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2023-05-02 - Årsstämma
2023-04-28 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-07-15 - Kvartalsrapport 2022-Q2
2022-04-29 - Kvartalsrapport 2022-Q1
2022-04-05 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2022-04-04 - Årsstämma
2022-02-11 - Bokslutskommuniké 2021
2021-10-29 - Kvartalsrapport 2021-Q3
2021-07-16 - Kvartalsrapport 2021-Q2
2021-05-11 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2021-05-10 - Årsstämma
2021-04-29 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-10-23 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-04-24 - Kvartalsrapport 2020-Q1
2020-04-03 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2020-04-02 - Årsstämma
2020-03-10 - Extra Bolagsstämma 2020
2020-02-07 - Bokslutskommuniké 2019
2019-10-25 - Kvartalsrapport 2019-Q3
2019-07-19 - Kvartalsrapport 2019-Q2
2019-05-07 - Extra Bolagsstämma 2019
2019-04-26 - Kvartalsrapport 2019-Q1
2019-04-09 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2019-04-08 - Årsstämma
2019-02-08 - Bokslutskommuniké 2018
2018-10-26 - Kvartalsrapport 2018-Q3
2018-07-20 - Kvartalsrapport 2018-Q2
2018-04-27 - Kvartalsrapport 2018-Q1
2018-04-10 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2018-04-09 - Årsstämma
2018-02-23 - Bokslutskommuniké 2017
2017-11-10 - Kvartalsrapport 2017-Q3
2017-08-18 - Kvartalsrapport 2017-Q2
2017-05-23 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2017-05-22 - Årsstämma
2017-05-15 - Kvartalsrapport 2017-Q1
2017-02-24 - Bokslutskommuniké 2016
2017-02-20 - Extra Bolagsstämma 2017
2016-11-04 - Kvartalsrapport 2016-Q3
2016-08-19 - Kvartalsrapport 2016-Q2
2016-05-25 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2016-05-24 - Årsstämma
2016-05-17 - Kvartalsrapport 2016-Q1
2016-02-23 - Bokslutskommuniké 2015
2015-11-06 - Kvartalsrapport 2015-Q3
2015-08-21 - Kvartalsrapport 2015-Q2
2015-05-07 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2015-05-06 - Årsstämma
2015-05-06 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-11-07 - Kvartalsrapport 2014-Q3
2014-08-22 - Kvartalsrapport 2014-Q2
2014-06-04 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2014-06-03 - Årsstämma
2014-05-09 - Kvartalsrapport 2014-Q1
2014-02-21 - Bokslutskommuniké 2013
2014-02-12 - Extra Bolagsstämma 2014
2013-11-06 - Kvartalsrapport 2013-Q3
2013-08-22 - Kvartalsrapport 2013-Q2
2013-05-03 - X-dag ordinarie utdelning EPIS B 0.00 SEK
2013-05-03 - Kvartalsrapport 2013-Q1
2013-05-02 - Årsstämma
2013-04-03 - Extra Bolagsstämma 2013
2013-02-21 - Bokslutskommuniké 2012
2012-11-21 - Kvartalsrapport 2012-Q3
2012-08-22 - Kvartalsrapport 2012-Q2
2012-06-04 - Årsstämma
2012-05-04 - Kvartalsrapport 2012-Q1
2012-02-21 - Bokslutskommuniké 2011
2011-11-21 - Kvartalsrapport 2011-Q3
2011-08-22 - Kvartalsrapport 2011-Q2
2011-07-20 - Split EPIS B 6:1
2011-06-30 - Årsstämma
2011-05-21 - Kvartalsrapport 2011-Q1
2011-05-13 - Extra Bolagsstämma 2011
2011-05-02 - Kvartalsrapport 2011-Q1
2011-02-18 - Bokslutskommuniké 2010
2010-08-30 - Extra Bolagsstämma 2010
LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Episurf Medical är ett fastighetsbolag med exponering mot en diversifierad portfölj av fastighetstillgångar. Bolaget har som mål att skapa värdetillväxt genom förvärv och förvaltning av nordiska fastigheter. Bolaget har även en medicinteknisk verksamhet som bygger på ett individanpassat implantat, Episealer® och tillhörande kirurgiska instrument, vilka används för att behandla broskskador i leder. Episurf Medicals huvudkontor ligger i Stockholm, Sverige.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Episurf Medical completes acquisition of property portfolio in Hudiksvall

2026-10-01 16:20:00

Episurf Medical AB (publ) (Nasdaq Stockholm: EPIS B) ("Episurf" or the "Company") has today, through a wholly owned subsidiary, completed the acquisition of eight properties in Hudiksvall with an agreed underlying property value of SEK 300 million. With the exception of the property Åvik 26:14, the properties constitute the Non-completed Property Portfolio described in the Company's press release of 30 December 2025. The properties have a total leasable area of approximately 16,300 m², annual rental income of approximately SEK 26.1 million and net operating income of approximately SEK 22.4 million. 

"The properties in Hudiksvall are fully let and largely recently renovated. Hudiksvalls kommun is the largest tenant with a lease running until 2035, and the completion increases the property segment's net operating income by more than SEK 22 million on an annual basis." 

- Jens Andersson, CEO, Episurf Medical 

The closing in brief 

On 30 December 2025, Episurf announced that the Company had entered into an agreement with Frusipe Intressenter Holding AB (the "Seller") regarding the acquisition of all shares in Frusipe Intressenter Target 1 AB (the "Target Company") (the "Acquisition"). In addition to holding and managing, through subsidiaries, a property portfolio consisting of a total of four properties (the "Completed Property Portfolio"), the Target Company had through a subsidiary entered into an agreement to acquire an additional property portfolio consisting of a total of nine properties in Hudiksvall, with a total agreed underlying property value of approximately SEK 470 million (the "Non-completed Property Portfolio"). The Acquisition of the Target Company was completed on 8 January 2026.[1]

Closing of the acquisition of the Non-completed Property Portfolio has now taken place with respect to eight of the nine properties. The property Åvik 26:14 is not included in the closing. 

The property portfolio has been developed by Västra Hamnen Holding AB and Västra Hamnen Utveckling AB. 

Purchase price and financing 

The agreed underlying property value of the acquired properties amounts to SEK 300 million. The financing has changed compared with previously published information, see below. 

Changed financing 

As set out in the press release of 30 December 2025, the preliminary purchase price concerning the Non-completed Property Portfolio was to be paid through directed issues to the Seller of Class B shares and convertible debentures convertible into Class B shares, corresponding to approximately 4.15 billion Class B shares. As payment for the acquired properties, a total of approximately 1.73 billion Class B shares have been issued, which is approximately 2.41 billion fewer Class B shares than previously communicated. The total dilution effect for existing shareholders resulting from the Acquisition will be lower than stated in the press release of 30 December 2025. The remaining part of the purchase price is paid with the Company's cash and cash equivalents. Existing loans in the acquired property companies are refinanced with new bank debt. 

Key figures for the acquired properties 

The eight properties have a total leasable area of approximately 16,334 m². Annual rental income amounts to approximately SEK 26.1 million and net operating income to approximately SEK 22.4 million, corresponding to a yield of approximately 7.5 percent on the agreed underlying property value. The average remaining lease period, weighted by rental income, amounts to approximately 5.4 years. The properties are fully let. 

The portfolio comprises the properties Åvik 26:16, Åvik 26:22, Sofiedal 12:6, Tuna-Fors 1:40, Tuna-Fors 2:23, Tuna-Fors 2:34, Tuna-Fors 2:36 and Tuna-Fors 4:8. 

About the properties 

Two of the properties are located in the Västra Hamnen district, approximately 1 km from Hudiksvall Central Station. Åvik 26:16 comprises a sports arena with two full-size halls, completed in autumn 2025 and let to Hudiksvalls kommun on a ten-year lease until 30 September 2035, as well as office premises. Åvik 26:22 is a healthcare centre let to Doktorama Söderhamn AB on a ten-year lease until 31 December 2035. 

The remaining six properties are located in the Tuna-Fors industrial and retail area close to the E4 motorway and comprise light industrial, retail and office premises. Tenants include Ahlsell, Byggmax, NCC Industry, Rexel, Anticimex and Trafikverket. 

For further information, please contact: 

Jens Andersson, CEO, Episurf Medical 

Tel: +46 (0) 768 55 67 02 

Email: jens.andersson@episurf.se

Jonathan Tillander, IR, Episurf Medical 

Tel: +46 (0) 760 76 80 22 

Email: jonathan.tillander@episurf.se

About Episurf Medical 

Episurf Medical is a property company with exposure to a diversified portfolio of property assets. The Company's objective is to create value growth through the acquisition and management of Nordic properties. The Company also has a medical technology operation based on the individualized implant Episealer® and associated surgical instruments, which are used to treat cartilage injuries in joints. Episurf Medical's head office is in Stockholm, Sweden. 

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU) No 596/2014. The information was submitted for publication, through the agency of the contact persons set out above, at 16:20 on 1 October 2026. 

[1]For further information regarding the Acquisition, see Episurf's press release of 30 December 2025.